RxDoctor Payments Data

Gary Matusow, DO

Gastroenterology · Egg Harbor Township, NJNPI 1033154463

Payments from drug & device makers

$11,664in general payments, 2019–2025

Across 475 payments — averaging $24.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Intercept Pharma Europe Ltd.$2K
  • Intercept Pharmaceuticals, Inc.$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$802
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$664
  • QOL Medical, LLC$661
  • plus $4K from 26 others

What the payments were for

  • Consulting fees$1502%
  • Food & beverage$8,51498%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,664 in reported general payments places this provider in the 85th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$84,652
Medicare patients
515
Services billed
756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib17$142,940
LinzessLinaclotide141$105,026
XifaxanRifaximin26$57,368
Alosetron Hcl40$51,843
OzempicSemaglutide24$24,973
Mesalamine35$21,143
VoqueznaVonoprazan Fumarate26$18,413
Lubiprostone24$3,496
Omeprazole254$2,653
Pantoprazole Sodium84$1,510
Lansoprazole13$1,504
Dicyclomine Hcl40$1,192
Ondansetron OdtOndansetron37$1,101
Cholestyramine LightCholestyramine14$879
LoperamideLoperamide Hcl33$831

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Linzess$2,159$247,965158 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$664$57,36826 claims
Novo NordiskOzempic$141$24,97324 claims
Phathom Pharmaceuticals, Inc.Voquezna$152$18,41326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Egg Harbor Township

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →